Summary
Global Markets Direct’s, ‘Bronchitis - Pipeline Review, H1 2016’, provides an overview of the Bronchitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bronchitis
- The report reviews pipeline therapeutics for Bronchitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bronchitis therapeutics and enlists all their major and minor projects
- The report assesses Bronchitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bronchitis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bronchitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bronchitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Boehringer Ingelheim GmbH
DBV Technologies S.A.
Hyundai Pharmaceutical Co., Ltd.
Invion Limited
Mucosis B.V.
Orbis Biosciences, Inc.
Recipharm AB
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bronchitis Overview 6
Therapeutics Development 7
Pipeline Products for Bronchitis - Overview 7
Bronchitis - Therapeutics under Development by Companies 8
Bronchitis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Bronchitis - Products under Development by Companies 12
Bronchitis - Companies Involved in Therapeutics Development 13
Boehringer Ingelheim GmbH 13
DBV Technologies S.A. 14
Hyundai Pharmaceutical Co., Ltd. 15
Invion Limited 16
Mucosis B.V. 17
Orbis Biosciences, Inc. 18
Recipharm AB 19
Bronchitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
BI-113608 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
erdosteine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
HOB-051 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
nadolol - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
nitric oxide - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
prednisone - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
respiratory syncytial virus vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SynGEM - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Bronchitis - Recent Pipeline Updates 41
Bronchitis - Dormant Projects 46
Bronchitis - Discontinued Products 48
Bronchitis - Product Development Milestones 49
Featured News & Press Releases 49
Oct 07, 2015: EVP R&D Dr Mitchell Glass discusses with BRR media data from the Phase 2 clinical trial of INV102 (nadolol) in Smoking Cessation 49
Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets 49
Apr 21, 2015: Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings 49
Jan 23, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants 50
Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 50
Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53
List of Tables
Number of Products under Development for Bronchitis, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Bronchitis - Pipeline by Boehringer Ingelheim GmbH, H1 2016 13
Bronchitis - Pipeline by DBV Technologies S.A., H1 2016 14
Bronchitis - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 15
Bronchitis - Pipeline by Invion Limited, H1 2016 16
Bronchitis - Pipeline by Mucosis B.V., H1 2016 17
Bronchitis - Pipeline by Orbis Biosciences, Inc., H1 2016 18
Bronchitis - Pipeline by Recipharm AB, H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Bronchitis Therapeutics - Recent Pipeline Updates, H1 2016 41
Bronchitis - Dormant Projects, H1 2016 46
Bronchitis - Dormant Projects (Contd..1), H1 2016 47
Bronchitis - Discontinued Products, H1 2016 48
List of Figures
Number of Products under Development for Bronchitis, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 10
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Targets, H1 2016 21
Number of Products by Stage and Targets, H1 2016 21
Number of Products by Mechanism of Actions, H1 2016 23
Number of Products by Stage and Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Molecule Types, H1 2016 27
Number of Products by Stage and Molecule Types, H1 2016 27
